Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8303868
Reference Type
Journal Article
Title
Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs
Author(s)
Hashimoto, K; Okamura, N; Shimizu, E; Iyo, M
Year
2004
Volume
4
Issue
2
Page Numbers
147-154
Language
English
DOI
10.2174/1568015043357011
Abstract
L-Glutamic acid (glutamate) is a major excitatory amino acid in the nervous system, and it is known that glutamate plays a major role in brain development, affecting neuronal migration, neuronal differentiation, axon genesis, and neuronal survival. Several lines of evidence suggest that a dysfunction in glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors might be involved in the pathophysiology of schizophrenia. In this review, we discuss the NMDA receptor hypofunction hypothesis of schizophrenia and the role of glutamate in the action of atypical antipsychotic drugs such as clozapine. In addition, as novel targets for therapeutic drugs for the treatment of schizophrenia, we focus on the glycine sites on NMDA receptors, metabotropic glutamate (mGlu) receptors, and AMPA receptors. This review covers known information about agonists for the glycine site on NMDA receptors, the glycine transporter inhibitors, the mGlu II receptor agonists, and the allosteric modulators of AMPA receptors.
Keywords
AMPA receptor; Antipsychotic drugs; D-Serine; Glutamate; Glycine transporter inhibitor; Metabotropic glutamate receptor; NMDA receptor; Schizophrenia
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity